It’s week 4 of 2020. Our stories for this edition of Industry Watch include; the potential of non-oncology drugs for treating cancer; the evolution of prescription drug regulation; the development of a new method for nerve regeneration; potential for growth hormone to improve post traumatic brain injury outcomes and a new method for improving the shelf life of vaccines.
Work to start on three possible China virus vaccines: epidemic response group
Research teams backed by a global coalition set up to fight epidemic diseases are to start work on developing potential vaccines against the new coronavirus that has caused a disease outbreak in China.
New Nerve-Growing Method Could Help Injured Soldiers and Others
Researchers have developed a biodegradable tube that acts as a guide for new nerve development along a damaged nerve ending. The tube promotes growth along the proper path, and the naturally occurring protein induces the nerve to grow faster.
Infections Account for a substantial amount of All Cancer Cases
An estimated 13% of all cancer cases in 2018 may be attributable to infections, concludes a new global survey. The primary causes were Helicobacter pylori, human papillomavirus (HPV), hepatitis B virus (HBV), and hepatitis C virus (HCV).
New method to enable the production of cheaper, longer-lasting vaccines
This new method uses novel technology to produce vaccines which require no refrigeration and have a shelf life of many years. These vaccines could be transported to regions of the world without electricity and refrigeration.
Could beta-blockers slow the spread of cancer?
New research from Monash University has suggested that anti-stress drugs, known as beta-blockers, could slow the spread of cancer in the body.
Traumatic brain injury impairs hormone production, disrupting sleep, cognition, and memory
Growth hormone replacement therapy for those with mild traumatic brain injury helped improve cognition, anxiety, and depression while reducing fatigue and sleep disturbances.
FDA Approval and Regulation of Pharmaceuticals, 1983-2018
The evolution of laws and standards affecting drug testing, the use of new approval programs and standards, expansions of the role and authority of the FDA, and changes in the number of drugs approved from the 1980s to 2018. All this an more is laid out in this interesting paper published in JAMA this month.
Dozens of non-oncology drugs can kill cancer cells
A study testing thousands of medicines in hundreds of cancer cell lines in the lab uncovers new tricks for many old drugs. The findings suggest a possible way to accelerate the development of new cancer drugs or repurpose existing drugs to treat cancer.